Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.
Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
Ciprofloxacin or amoxicillin plus clavulanic acid
Reductions in pre-dose (trough) MPA concentrations of about 50% have been reported in renal
transplant recipients in the days immediately following commencement of oral ciprofloxacin or
amoxicillin plus clavulanic acid. This effect tended to diminish with continued antibiotic use and to
cease within a few days of antibiotic discontinuation. The change in pre-dose level may not accurately
represent changes in overall MPA exposure. Therefore, a change in the dose of mycophenolate mofetil
should not normally be necessary in the absence of clinical evidence of graft dysfunction. However,
close clinical monitoring should be performed during the combination and shortly after antibiotic
treatment.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Ciprofloxacin or amoxicillin plus clavulanic acid
Reductions in pre-dose (trough) MPA concentrations of about 50% have been reported in renal
transplant recipients in the days immediately following commencement of oral ciprofloxacin or
amoxicillin plus clavulanic acid. This effect tended to diminish with continued antibiotic use and to
cease within a few days of antibiotic discontinuation. The change in pre-dose level may not accurately
represent changes in overall MPA exposure. Therefore, a change in the dose of mycophenolate mofetil
should not normally be necessary in the absence of clinical evidence of graft dysfunction. However,
close clinical monitoring should be performed during the combination and shortly after antibiotic
treatment.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Ciprofloxacin or amoxicillin plus clavulanic acid
Reductions in pre-dose (trough) MPA concentrations of about 50% have been reported in renal
transplant recipients in the days immediately following commencement of oral ciprofloxacin or
amoxicillin plus clavulanic acid. This effect tended to diminish with continued antibiotic use and to
cease within a few days of antibiotic discontinuation. The change in pre-dose level may not accurately
represent changes in overall MPA exposure. Therefore, a change in the dose of mycophenolate mofetil
should not normally be necessary in the absence of clinical evidence of graft dysfunction. However,
close clinical monitoring should be performed during the combination and shortly after antibiotic
treatment.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Ciprofloxacin or amoxicillin plus clavulanic acid
Reductions in pre-dose (trough) MPA concentrations of about 50% have been reported in renal
transplant recipients in the days immediately following commencement of oral ciprofloxacin or
amoxicillin plus clavulanic acid. This effect tended to diminish with continued antibiotic use and to
cease within a few days of antibiotic discontinuation. The change in pre-dose level may not accurately
represent changes in overall MPA exposure. Therefore, a change in the dose of mycophenolate mofetil
should not normally be necessary in the absence of clinical evidence of graft dysfunction. However,
close clinical monitoring should be performed during the combination and shortly after antibiotic
treatment.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Version 2026-05-07T14:22:00Z · SHA-256 8464b0a5294445d85b3f9b902633989ca6f57af3990241a80eda4979936ba419 · Passage 4bd1292f9e3f6d1853c880dd51e7a3e55450c016d6db3b80ef4f0f7a6ca28174 · Zeichen 3108–3857 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.